Three audiences. Three ways we work with you.
Whether you are designing a clinical trial, running a translational laboratory, or monitoring oncology patients, we shape ultra-sensitive ctDNA around how you actually work. Pick the page that sounds like you.
Validate MRD endpoints. Move faster.
For pharma teams and CROs running phase I to III oncology trials in Europe.
- Trial-arm cost reduction through earlier endpoint signal
- MRD endpoints validated in head-to-head studies
- EU regulatory readiness, GDPR-native logistics
- Protocol design support and co-publication
See signals others miss.
-
Low-AF detection in low-input samples
-
Send samples, or run SiMSen-Seq on your own instruments
-
Full raw data access, open pipeline, client bioinformatics collaboration
-
Co-publication on translational findings
Catch relapse before imaging does.
- Personalised ctDNA monitoring per patient
- Lead time over imaging-based surveillance
- EUR / SEK / GBP pricing, local logistics, time-zone working hours
- Interpretation support
TRUSTED BY LEADING EUROPEAN CLINICS, HOSPITALS AND BIOTECHS
Two ways to work with us. Same chemistry, same sensitivity
You can ship samples to our accredited lab, or you can run SiMSen-Seq on your own instruments. Whichever you choose, you keep the data and the science.
Full-service
Ship samples to our ISO 15189-compliant lab in Sweden. We handle library prep, sequencing, variant calling and reporting.
LabSuite
Run SiMSen-Seq on your own Illumina instruments. We supply reagents, software, training and ongoing support.
Speak to our scientific team.
A real human, in CET/CEST time zone, who has run samples like yours.